Test/Investigation
Adalimumab level and Ab
Site(s) or Laboratory offering Test/Investigation
Referral laboratory (Immunology)
Units
AU/mL
Also Known as/Frequency of Test
Humira; Exemptia
Indications
Diseases such as ulcerative colitis and Crohn’s disease respond to anti-Tumour Necrosis Factor alpha (TNF-α) therapy (e.g. Adalimumab/ infliximab). During treatment some patients can generate high levels of anti-drug antibodies (ADAs) which negate therapeutic effect. The serum concentration of the drug immediately prior to re-infusion (trough level) is needed to interpret the relevance of ADAs. Please refer to specialist guidelines for monitoring
Comments/Precautions
Plasma NOT acceptable. Referred outside of EPA
Sample type
Serum
Turnaround times (TAT) Urgent/Routine/GP or OPD
2 weeks
Reference intervals (adult unless stated)
<5 AU/mL
Therapeutic values for Adalimumab (or biosimilar) vary according to pathology